Jolly Good and Teijin Pharma Form a Partnership to Develop VR Digital Therapeutics for Depression
News provided by
Share this article
Share this article
TOKYO, April 23, 2021 /PRNewswire/ Jolly Good Inc. ( Jolly Good ) and Teijin Pharma Ltd. ( Teijin Pharma ) have signed a business partnership agreement to develop VR digital therapeutics ( VR DTx ) for Major Depressive Disorder (MDD). Together, they will promote the development of VR DTx for depression, aiming for PMDA regulatory approval.
Background of this agreement
Jolly Good and Teijin Pharma Form a Partnership to Develop VR Digital Therapeutics for Depression
This all started when Jolly Good won Home Healthcare Award in a program held by Teijin in Dec., 2020. Focusing of Jolly Good s development of Cognitive Behavioral Therapy VR ( CBT VR ) for psychiatric disorders, this partnership will leverage Jolly Good s VR technology and Teijin Pharma s expertise in knowledge and strategic skills. They have agreed that the
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Jolly Good Newly Establishes CBT VR Specialist Department with Clinical Psychiatrists
April 1, 2021 GMT
TOKYO, April 1, 2021 /PRNewswire/ Leading Japanese medical VR company Jolly Good Inc. has recently established a specialized DTx Division to develop digital therapeutics (hereinafter “DTx”) using VR and AI technologies.
Dr. Ayako Kanie and Dr. Aiichiro Nakajima, psychiatrists and leaders in the development of cognitive behavioral therapy at top research institutes in Japan, will officially participate in Jolly Good. The company has been developing social skill-training VR for developmental disabilities and digital therapeutics VR for depression. After agreeing that Jolly Good’s high-quality VR could be effective for mental illnesses, both doctors made the decision to participate.